Novocure Ltd
NVCR12.040USD
-0.500-3.99%
Handelsschluss 07/25, 16:00（ET）Kurse um 15 Minuten verzögert
1.35BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Novocure Ltd Unternehmen
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Unternehmensinformationen
BörsenkürzelNVCR
Name des UnternehmensNovocure Ltd
IPO-datumOct 01, 2015
Gegründet am2000
CEOMs. Ashley Cordova
Anzahl der mitarbeiter1488
WertpapierartOrdinary Share
GeschäftsjahresendeOct 01
AddresseNo. 4 The Forum
StadtSAINT HELIER
BörseNASDAQ Global Select Consolidated
LandJersey
PostleitzahlJE2 4UF
Telefon441534756700
Websitehttps://www.novocure.com/
BörsenkürzelNVCR
IPO-datumOct 01, 2015
Gegründet am2000
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
93.15M
60.10%
Germany
18.72M
12.08%
France
17.86M
11.52%
Other EMEA countries
11.94M
7.70%
Japan
8.71M
5.62%
Greater China
4.62M
2.98%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 23
Aktualisiert: Wed, Jul 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
48.81%
Investment Advisor/Hedge Fund
14.72%
Hedge Fund
12.72%
Individual Investor
10.05%
Research Firm
1.57%
Sovereign Wealth Fund
0.87%
Pension Fund
0.42%
Bank and Trust
0.32%
Venture Capital
0.12%
Other
10.39%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
675
112.27M
100.70%
-3.75M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
2023Q1
864
93.47M
88.04%
+2.38M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
16.49M
14.79%
+257.14K
+1.58%
Mar 31, 2025
The Vanguard Group, Inc.
11.23M
10.07%
-544.61K
-4.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.78M
7.88%
-135.87K
-1.52%
Mar 31, 2025
Wyss (Hansjorg)
8.14M
7.3%
--
--
Apr 04, 2025
Soleus Capital Management, L.P.
5.52M
4.95%
+2.78M
+101.53%
Mar 31, 2025
Capital World Investors
5.22M
4.68%
+400.00K
+8.31%
Mar 31, 2025
State Street Global Advisors (US)
2.59M
2.32%
-52.73K
-2.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.46M
2.21%
+63.41K
+2.64%
Mar 31, 2025
BlackRock Financial Management, Inc.
2.06M
1.85%
+71.86K
+3.61%
Mar 31, 2025
Marshall Wace LLP
1.81M
1.62%
+1.54M
+567.13%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Global X HealthTech ETF
1.92%
SPDR S&P Health Care Equipment ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.63%
Amplify BlueStar Israel Technology ETF
0.93%
iShares Health Innovation Active ETF
0.53%
VanEck Israel ETF
0.42%
First Trust Small Cap Growth AlphaDEX Fund
0.34%
Global X Aging Population ETF
0.34%
Nuveen ESG Small-Cap ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
Mehr Anzeigen
Global X HealthTech ETF
Anteil1.92%
SPDR S&P Health Care Equipment ETF
Anteil1.85%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.63%
Amplify BlueStar Israel Technology ETF
Anteil0.93%
iShares Health Innovation Active ETF
Anteil0.53%
VanEck Israel ETF
Anteil0.42%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.34%
Global X Aging Population ETF
Anteil0.34%
Nuveen ESG Small-Cap ETF
Anteil0.25%
ProShares Ultra Nasdaq Biotechnology
Anteil0.23%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
